News | August 12, 2021
Hester Biosciences posts PAT of Rs 11.01 cr in Q1FY22
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Marks first international filing for Evofem’s single-dose oral treatment
IND application for EB-003 expected in early 2026
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Subscribe To Our Newsletter & Stay Updated
